{
    "clinical_study": {
        "@rank": "97476", 
        "acronym": "COHERE", 
        "arm_group": [
            {
                "arm_group_label": "Continuous heparin infusion group", 
                "arm_group_type": "Active Comparator", 
                "description": "continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural."
            }, 
            {
                "arm_group_label": "Intermittent heparin infusion group", 
                "arm_group_type": "Active Comparator", 
                "description": "Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician."
            }
        ], 
        "brief_summary": {
            "textblock": "Optimal anticoagulation using heparin with close attention to maintain therapeutic dosing\n      during the procedure is important.\n\n      Randomized comparison of continuous and intermittent heparin infusion during catheter\n      ablation of Atrial Fibrillation."
        }, 
        "brief_title": "Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Coagulation; Intravascular", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "detailed_description": {
            "textblock": "Intravenous heparin was used during the procedure to prevent catheter-induced thrombosis.\n\n      heparin is administered during the procedure to achieve recommended activation clotting\n      times (ACT) values, typically >300 seconds to prevent thromboemboli during the procedure.\n\n      Most of the practitioners was that ACT level should be checked at 30- to 60-minute intervals\n      and then have injected intermittently.\n\n      intermittent heparin infusion, concentration is great changed because the heparin has\n      30minutes half-period.\n\n      researchers postulate that a constant therapeutic concentrations would be beneficial to\n      continuous infusion than intermittent infusion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Atrial Fibrillation, Radiofrequency catheter ablation scheduled\n\n        Exclusion Criteria:\n\n          -  Clinical trial denied"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935557", 
            "org_study_id": "COHERE"
        }, 
        "intervention": [
            {
                "arm_group_label": "Continuous heparin infusion group", 
                "description": "continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.", 
                "intervention_name": "Continuous heparin infusion", 
                "intervention_type": "Drug", 
                "other_name": "Continuous heparin infusion"
            }, 
            {
                "arm_group_label": "Intermittent heparin infusion group", 
                "description": "Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.", 
                "intervention_name": "Intermittent heparin infusion", 
                "intervention_type": "Drug", 
                "other_name": "Intermittent heparin infusion"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium heparin", 
                "Heparin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Continuous heparin infusion", 
            "Intermittent heparin infusion", 
            "during catheter ablation"
        ], 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul st. mary's hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation", 
        "overall_contact": {
            "email": "oys@catholic.ac.kr", 
            "last_name": "Yong Seog Oh, MD", 
            "phone": "82-2-2258-1141"
        }, 
        "overall_official": {
            "affiliation": "Seoul St. Mary's Hospital", 
            "last_name": "Yong Seog Oh, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "therapeutic ACT retention rate during procedure", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935557"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul St. Mary's Hospital", 
            "investigator_full_name": "Yong Seog Oh", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Seoul St. Mary's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul St. Mary's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}